Alison Moore is recorded as Board Member at Codexis, Inc. (CDXS) since January 1, 2025 and CEO at Codexis, Inc. (CDXS). The newest filing on record that lists Alison Moore as CEO and Board Member at Codexis, Inc. (CDXS) is dated April 28, 2026. Allogene Therapeutics, Inc. reported in an 8-K filed April 20, 2023 that Alison Moore resigned as Chief Technical Officer, effective April 28, 2023. The proxy statement of Codexis, Inc. reports total compensation of $2,323,279 for Alison Moore in fiscal 2025, including a base salary of $524,732. Disclosed compensation is on record for 7 fiscal years. Alison Moore has spoken on 4 earnings calls across 1 company, most recently for Codexis, Inc. on August 11, 2026. Codexis, Inc. is classified in the Biotechnology industry within the Healthcare sector. Allogene Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Codexis, Inc. includes Alison Moore, Ph.D. (CEO and CTO), Dr. Stephen Dilly (CEO), Georgia Erbez (CFO) and 7 others.
“On April 18, 2023, Alison Moore, the Chief Technical Officer of Allogene Therapeutics, Inc. (the "Company"), notified the Company of her decision to resign effective April 28, 2023 to pursue other opportunities.”
Allogene Therapeutics, Inc. Form 8-K, filed April 20, 2023
· Read the filing
Alison Moore on recent calls
“Codexs generates manufacturing solutions using high-performance engineered enzymes. The investment of over 20 years of our expertise is playing out in our pharma biocatalysis pipeline, which supports 14 commercial products and a pipeline of 15 in Phase II and III clinical development.”
“While it's been a short eight weeks since our last call, we've accomplished a lot at Codexis. We are pleased to report another strong quarter and are busy preparing for the TIDES conference next week, where we will present important new data on our ecosynthesis technology.”
“At Codexis, Inc., our mission is to generate manufacturing solutions using biocatalytic enzymes. Building on our history of innovative enzymes and our established relationships with the biopharmaceutical industry, we are now focused on RNA medicine.”
“I've been part of Codexis for the last five years, first as a board member and then as a member of executive leadership. I've had the pleasure of seeing Codexis evolve into an innovation leader in oligonucleotide manufacturing.”
